ORPHINA
DEAD

Serial Number

90076663

Owner

Orphina LLC

First Use Date

Oct 8, 2013

Filing Date

Jul 27, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ORPHINA Trademark

Serial Number: 90076663

ORPHINA is a trademark filed by Orphina LLC on July 27, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Orphina LLC (2 trademarks)

4474 Park Granada Unit 8964
Calabasas, CA 91372

Entity Type: 16

Trademark Details

Filing Date

July 27, 2020

Registration Date

Not Registered

First Use Anywhere

October 8, 2013

First Use in Commerce

November 6, 2015

Goods & Services

Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention of neuromuscular, neurological, musculoskeletal, genetic, metabolic, orthopedic, and oncologic diseases; Pharmaceutical preparations for the prevention of rare diseases; Pharmaceutical preparations for the prevention of muscle wasting and muscle degeneration; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of neuromuscular, neurological, musculoskeletal, genetic, metabolic, orthopedic, and oncologic diseases; Pharmaceutical preparations for the treatment of rare diseases; Pharmaceutical preparations for the treatment of muscle wasting and muscle degeneration; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for biologics, gene therapy, or stem cell therapy; Pharmaceutical preparations for muscle function improvement; Stem cells for medical purposes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 2, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 2, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 12, 2020 GNRN
NON-FINAL ACTION E-MAILED
Nov 12, 2020 GNRT
NON-FINAL ACTION WRITTEN
Nov 12, 2020 CNRT
ASSIGNED TO EXAMINER
Nov 12, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 26, 2020 NWOS
NEW APPLICATION ENTERED
Jul 30, 2020 NWAP